Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine in Severe COPD
NCT02211118Phase 4Completed
- Sponsor
- Dayton VA Medical Center
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine in anxiety disorder, sponsored by Dayton VA Medical Center. Primary endpoints: Modified Observer's Assessment of Alertness/Sedation up to 5 hours and Sedation Visual Analog Scale up to 5 hours. Started Oct 2014; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT02211118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211118.